Fiera Capital Corp Bei Gene, Ltd. Transaction History

Fiera Capital Corp

  • $30.3 Billion
  • Q4 2024

A detailed history of Fiera Capital Corp transactions in Bei Gene, Ltd. stock. As of the latest transaction made, Fiera Capital Corp holds 8,442 shares of BGNE stock, worth $1.91 Million. This represents 0.01% of its overall portfolio holdings.

Number of Shares
8,442
Previous 6,011 40.44%
Holding current value
$1.91 Million
Previous $1.35 Million 15.57%
% of portfolio
0.01%
Previous 0.0%

Shares

27 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q4 2024

Jan 29, 2025
BUY
$174.72 - $246.04 $424,744 - $598,123
2,431 Added 40.44%
8,442 $1.56 Million
Q3 2024

Nov 01, 2024
BUY
$143.93 - $224.51 $327,440 - $510,760
2,275 Added 60.89%
6,011 $1.35 Million
Q2 2024

Aug 01, 2024
BUY
$129.52 - $174.32 $152,315 - $205,000
1,176 Added 45.94%
3,736 $533,000
Q1 2024

Aug 22, 2024
SELL
$141.8 - $181.47 $166,756 - $213,408
-1,176 Reduced 31.48%
2,560 $400,000
Q1 2024

May 01, 2024
SELL
$141.8 - $181.47 $825,276 - $1.06 Million
-5,820 Reduced 69.45%
2,560 $400,000
Q4 2023

Aug 22, 2024
SELL
$158.67 - $201.58 $31,733 - $40,316
-200 Reduced 2.33%
8,380 $1.51 Million
Q4 2023

Feb 08, 2024
SELL
$158.67 - $201.58 $31,733 - $40,316
-200 Reduced 2.33%
8,380 $1.51 Million
Q3 2023

Aug 22, 2024
BUY
$179.87 - $225.13 $871,290 - $1.09 Million
4,844 Added 129.66%
8,580 $1.54 Million
Q3 2023

Nov 09, 2023
BUY
$179.87 - $225.13 $41,549 - $52,005
231 Added 2.77%
8,580 $1.54 Million
Q2 2023

Aug 09, 2023
SELL
$178.3 - $266.78 $33,520 - $50,154
-188 Reduced 2.2%
8,349 $1.49 Million
Q1 2023

Apr 26, 2023
BUY
$215.53 - $274.5 $57,330 - $73,017
266 Added 3.22%
8,537 $1.84 Million
Q4 2022

Feb 08, 2023
BUY
$125.51 - $229.3 $50,580 - $92,407
403 Added 5.12%
8,271 $1.82 Million
Q1 2022

May 09, 2022
SELL
$146.52 - $269.56 $19.4 Million - $35.7 Million
-132,515 Reduced 94.4%
7,868 $1.48 Million
Q4 2021

Feb 08, 2022
SELL
$248.56 - $389.34 $1.21 Million - $1.89 Million
-4,856 Reduced 3.34%
140,383 $38 Million
Q3 2021

Nov 12, 2021
SELL
$249.6 - $403.14 $638,726 - $1.03 Million
-2,559 Reduced 1.73%
145,239 $52.7 Million
Q2 2021

Aug 11, 2021
SELL
$292.75 - $367.01 $1.03 Million - $1.29 Million
-3,503 Reduced 2.32%
147,798 $27.8 Million
Q1 2021

May 11, 2021
SELL
$260.64 - $382.12 $1.05 Million - $1.53 Million
-4,014 Reduced 2.58%
151,301 $52.7 Million
Q4 2020

Feb 09, 2021
BUY
$221.31 - $316.61 $133,007 - $190,282
601 Added 0.39%
155,315 $40.1 Million
Q3 2020

Nov 12, 2020
SELL
$189.18 - $286.44 $862,282 - $1.31 Million
-4,558 Reduced 2.86%
154,714 $44.3 Million
Q2 2020

Aug 07, 2020
SELL
$123.9 - $195.41 $655,431 - $1.03 Million
-5,290 Reduced 3.21%
159,272 $30 Million
Q1 2020

May 08, 2020
SELL
$121.84 - $173.19 $1.27 Million - $1.8 Million
-10,396 Reduced 5.94%
164,562 $20.3 Million
Q4 2019

Feb 06, 2020
SELL
$115.78 - $208.34 $1.97 Million - $3.54 Million
-16,992 Reduced 8.85%
174,958 $29 Million
Q3 2019

Nov 12, 2019
SELL
$120.61 - $148.29 $127,605 - $156,890
-1,058 Reduced 0.55%
191,950 $23.5 Million
Q2 2019

Aug 12, 2019
SELL
$113.99 - $146.86 $1.5 Million - $1.93 Million
-13,154 Reduced 6.38%
193,008 $23.9 Million
Q1 2019

May 10, 2019
SELL
$122.82 - $151.83 $1.14 Million - $1.41 Million
-9,302 Reduced 4.32%
206,162 $27.2 Million
Q4 2018

Feb 12, 2019
BUY
$107.01 - $175.15 $22.4 Million - $36.7 Million
209,568 Added 3554.41%
215,464 $30.2 Million
Q3 2018

Nov 13, 2018
BUY
$152.62 - $189.66 $899,847 - $1.12 Million
5,896 New
5,896 $1.02 Million

Others Institutions Holding BGNE

# of Institutions
254
Shares Held
45.1M
Call Options Held
131K
Put Options Held
95.6K
View Full List

About BeiGene, Ltd.

BGNE Quotes by TradingView
  • Ticker BGNE
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 103,700,000
  • Market Cap $23.5B
  • Description
  • BeiGene, Ltd., a biotechnology company, focuses on discovering, developing, manufacturing, and commercializing various medicines worldwide. Its products include BRUKINSA to treat relapsed/refractory (R/R) mantle cell lymphoma; Tislelizumab to treat R/R classical Hodgkin's lymphoma; REVLIMID to treat multiple myeloma; VIDAZA to treat myelodysplas...
More about BGNE
Track This Portfolio

Track Fiera Capital Corp Portfolio

Follow Fiera Capital Corp and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Fiera Capital Corp, based on Form 13F filings with the SEC.

News

Stay updated on Fiera Capital Corp with notifications on news.

Choose your preferred platform and Sign Up 👇 Telegram Email